Table of Contents

CHAPTER 1. OVERALL FRAMEWORK TO GENERIC DRUG DEVELOPMENT AND PATENT LITIGATION
§ 1:1 Pathways to brand drug development
§ 1:2 Pathways to generic drug development
§ 1:3 Legal aspects of the generic drug development pathway for judges and lawyers

CHAPTER 2. INTRODUCTION TO PATENTS
I. PATENT BASICS
§ 2:1 In general
§ 2:2 Basic patent application process
§ 2:3 Structural organization of a patent

II. PATENT CLAIMS
§ 2:4 Importance of patent claims
§ 2:5 Person of ordinary skill in the art (POSITA)
§ 2:6 Organizational structure of the claim
§ 2:7 —Preamble
§ 2:8 —Transition phrase
§ 2:9 —Body of the claim
§ 2:10 Conclusion

III. STATUTORY PROVISIONS INTRODUCTION
§ 2:11 Common statutory provisions of the patent law

CHAPTER 3. COMMON TYPES OF PHARMACEUTICAL PATENTS
§ 3:1 Base chemical/compound claims
§ 3:2 Salts, esters, and solvates
§ 3:3 Enantiomers
§ 3:4 —History of enantiomer patentability
CHAPTER 4. FOUNDATIONS OF PATENT VALIDITY AND INVALIDITY

I. GENERALLY

§ 4:1 In general
§ 4:2 Claim construction breadth and invalidity: Broad constructions to invalidate or narrow constructions to avoid infringement

II. PRIOR ART

§ 4:3 Burdens of proof under Clear and Convincing Evidence—Prior art—Considered or not considered by examiner
§ 4:4 Burdens of proof—Prior art—Sources
§ 4:5 — —Fully presented and vetted
§ 4:6 — —Cited but not vetted
§ 4:7 — —Not cited

III. PRACTICING THE PRIOR ART

§ 4:8 Defense to infringement
§ 4:9 Practicing the prior art by replicating examples of the prior art—Inherent anticipation by replicating prior art examples

IV. GENUS AND SPECIES

§ 4:10 Interpretation
§ 4:11 Case study—Genus and species: Zyprexa® (Olanzapine)
§ 4:12 Genus species—Written description of the genus

CHAPTER 5. SECTION 101’S SUBJECT MATTER & UTILITY
§ 5:1 Patentable subject matter generally
§ 5:2 Mayo 2-Part Test
§ 5:3 Printed Matter Doctrine
§ 5:4 Patentable Subject Matter—Printed Matter Doctrine 2-Part Test
§ 5:5 Patentable subject matter—Pharmaceutical Patents
§ 5:6 —USPTO guidelines for pharma patents
§ 5:7 —Pharmaceuticals and concepts related to data comparisons with mental steps or analogous human mental work
§ 5:8 —Pharmaceuticals and concepts relating to organizing or analyzing information
§ 5:9 Pharmaceutical patent utility
§ 5:10 Pharmaceutical patent utility and specific methods of use of compound
§ 5:11 Pharmaceutical patent utility and enablement
§ 5:12 Pharmaceutical patent utility and benefits of priority application dates
§ 5:13 Generic company litigation strategies for section 101 invalidity
§ 5:14 Patentable subject matter issues in pharmaceutical patents—Selected cases
§ 5:15 Summary of Section 101 cases involving diagnostics versus method claims
§ 5:16 Summary of diagnostic claims treatment under Section 101
§ 5:17 Summary of method of treatment claims under Section 101
§ 5:18 Summary of method of preparation claims under section 101

CHAPTER 6. NOVELTY AND LOSS OF RIGHTS UNDER SECTION 102
§ 6:1 Novelty and “new” inventions
§ 6:2 Novelty under the new AIA
§ 6:3 “Old” Section 102(a)
CHAPTER 7. OBVIOUSNESS UNDER SECTION 103

I. BACKGROUND TO OBVIOUSNESS

§ 7:1 Inventions more than trivial variations
§ 7:2 *Graham v. Deere*factors—Primary obviousness factors
§ 7:3 Timing of obviousness inquiry
§ 7:4 Guarding against hindsight—Motivation, suggestion, teaching (MST) to combine prior art
§ 7:5 —Combination of references—Flowing from the prior art
§ 7:6 —References—From nature of problem to be solved
§ 7:7 Secondary indicia of obviousness
TABLE OF CONTENTS

§ 7:8 Unexpected results of the invention
§ 7:9 Long-felt need for the invention
§ 7:10 Failure of others to make the invention
§ 7:11 Copying by others—Benign factor in obviousness
§ 7:12 —Active ingredient
§ 7:13 —Formulation
§ 7:14 Licensing by others
§ 7:15 Commercial success—Generic drug infringement cases
§ 7:16 Skepticism by others and proof of nonobviousness
§ 7:17 Third-party praise and awards
§ 7:18 Chemical similarity—Chemical homology, isomerism, and structural similarity
§ 7:19 —Structural obviousness of chemical compounds
§ 7:20 —Isomers and obviousness
§ 7:21 Conclusion

II. OBVIOUSNESS & INVALIDITY

§ 7:22 Invalidity defense
§ 7:23 USPTO guidelines
§ 7:24 Combining prior art elements according to known methods to yield predictable results
§ 7:25 —Simple substitution of one known element for another to obtain predictable results
§ 7:26 Known techniques to improve similar devices, methods, or products
§ 7:27 Applying known technique to yield predictable results
§ 7:28 “Obvious to try”—Choosing from finite number of items
§ 7:29 —Role of common sense
§ 7:30 —Applicability to enantiomers, salt selection, and extended release (ER) formulations
§ 7:31 Market forces and design considerations
§ 7:32 Teaching, suggestion, or motivation in the prior art
§ 7:33 Person of ordinary skill in the art (POSITA)
§ 7:34 —The ordinary skilled artisan is not the inventor
§ 7:35 Structural obviousness—Breaking compound patents and the lead compound analysis
§ 7:36 ——Structural obviousness and lead compound analysis—Case study on pioglitazone
§ 7:37 —Lansoprazole versus rabeprazole
CHAPTER 8. SECTION 112’S BEST MODE

A. STATUTORY PROVISIONS: SPECIFICATION

§ 8:1 Role of the specification
§ 8:2 Section 112(a) (Pre-AIA Section 112, first paragraph)
§ 8:3 —Best mode requirement
§ 8:4 Patent invalidity theories under Section 112—Best mode requirement
§ 8:5 Using inequitable conduct to challenge best mode violations when invalidity is not allowed

CHAPTER 9. SECTION 112’S ENABLEMENT

§ 9:1 Role of the specification
§ 9:2 Section 112(a) (Pre-AIA Section 112, first paragraph)
§ 9:3 —Enablement requirement basics
§ 9:4 —Quick Summary
§ 9:5 Patent invalidity theories under Section 112
§ 9:6 —Lack of enablement
§ 9:7 ——Gap filling enablement with common knowledge and inadvertent obviousness
§ 9:8 ——Undue experimentation
§ 9:9 ——“How to make”
§ 9:10 ——“How to use”
§ 9:11 ——In vitro to in vivo teaching
§ 9:12 ——Effective amounts
§ 9:13 Contrasting enablement and best mode

CHAPTER 10. SECTION 112’S WRITTEN DESCRIPTION

§ 10:1 Role of the specification
§ 10:2 Section 112(a) (Pre-AIA Section 112, first paragraph)
§ 10:3 Written description
TABLE OF CONTENTS

§ 10:4 Patent invalidity theories under Section 112: written description invalidity
§ 10:5 Written description—Ranges in the specification
§ 10:6 Broad claim constructions can lead to written description invalidity
§ 10:7 Written description invalidity and mechanics of written description challenge
§ 10:8 Negative limitations in claims and specification support

CHAPTER 11. SECTION 112’S INDEFINITENESS
§ 11:1 Section 112(b) (Pre-AIA Section 112, second paragraph): claim precision and boundaries
§ 11:2 Section 112, second paragraph: claim precision, indefiniteness, and boundaries
§ 11:3 Indefiniteness: failure of ability to measure and testing
§ 11:4 Indefiniteness and what the inventor regards as invention
§ 11:5 Indefiniteness and rebuttable presumption in claim amendments to avoid ambiguity

CHAPTER 12. SECTION 112’S DEPENDENT AND MEANS PLUS FUNCTION CLAIMS
§ 12:1 Section 112(c)-(d) (Pre-AIA Section 112, third and fourth paragraph): Dependent claims
§ 12:2 Section 112(f) (Pre-AIA Section 112, sixth paragraph): means plus function claims

CHAPTER 13. GENUS AND SPECIES
§ 13:1 What is a genus and species
§ 13:2 Anticipation of genus and species patents
§ 13:3 Obviousness of genus and species
§ 13:4 Written description support for genus in view of disclosure of species
§ 13:5 Case study—Genus and species: Zyprexa® (Olanzapine)
CHAPTER 14. CLAIMING PRIORITY PROVISIONALS CONTINUATIONS AND DIVISIONALS

§ 14:1 Concept of claiming priority or benefit to earlier filing date
§ 14:2 Provisional patent applications
§ 14:3 Priority and earliest filing dates
§ 14:4 Section 119: claiming foreign priority dates to U.S. provisional applications
§ 14:5 Section 119(e): provisional application prior art date under pre-AIA 102(e) and AIA 102(a)(2)
§ 14:6 Section 119: claiming foreign priority—Claim for priority must include a specific reference to earlier filed foreign application
§ 14:7 Mechanics of claiming priority and benefits to earlier filing dates
§ 14:8 Section 119: claiming foreign priority— Tool for evaluating prior art effect
§ 14:9 —Prior Art and section 119(a) before and after the AIA
§ 14:10 Claiming the benefit of earlier-filed applications under Section 120 & 121
§ 14:11 Continuation applications for a different invention using the same specification
§ 14:12 Claim for benefit of earlier filing date under section 120 must include a specific reference to earlier filed application
§ 14:13 Divisional applications for examiner-mandated restrictions to different inventions
§ 14:14 Divisional applications and safe harbor provision of section 121 for divisional applications
§ 14:15 Continuation-in-part applications—Introducing new matter
§ 14:16 Written description, enablement, and best mode—Breaking chains of priority to invalidate later patents
§ 14:17 Rolling provisionals allow for chains of priority
§ 14:18 Importance of adequate disclosure to support later filed applications

CHAPTER 15. CLAIM CONSTRUCTION IN PATENT INFRINGEMENT

§ 15:1 Generally
§ 15:2 Basic infringement test
§ 15:3 Claim construction generally
§ 15:4 Evidence considered in claim construction
§ 15:5 —Intrinsic evidence must be considered first and mandatory evidence
§ 15:6 —Extrinsic evidence can be considered and permissive evidence
§ 15:7 —Dictionaries and treatises as sources of evidence of claim meaning
§ 15:8 Customary claim construction rules
§ 15:9 Tools for the generic company
§ 15:10 Specification clearly defines claim term
§ 15:11 Claim term is implicitly defined by consistent use throughout specification
§ 15:12 Pattern of examples in specification deduces claim meaning
§ 15:13 Embodiment is the invention
§ 15:14 Specification disavows particular meaning
§ 15:15 Specification explicitly disclaims definition
§ 15:16 Limiting the claim scope because consistent with invention’s purpose
§ 15:17 Specification contains implicit disclaimer of definition
§ 15:18 Specifications and underclaiming—Claiming less than you could have
§ 15:19 Prosecution history as intrinsic evidence—Mandatory or permissive evidence
§ 15:20 Using Inter Partes Review (IPR) and Post-Grant Review (PGR)
§ 15:21 Prosecution history contains narrow definition when ordinary meaning is unclear
§ 15:22 Claim term is narrowed because of disclaimer of ordinary meaning in prosecution history
§ 15:23 Using prosecution history of parent application in subsequent applications
§ 15:24 Choosing narrow claim scope when competing scopes exist
§ 15:25 Claim differentiation and interpreting claims of different scope
§ 15:26 Inexact modifiers or relative terminology
§ 15:27 Illustration regarding scope of “about”
§ 15:28 Timing of claim construction in view of issued patent
§ 15:29 Special Topic in Claim Construction for
CHAPTER 16. LITERAL INFRINGEMENT

§ 16:1 Generally
§ 16:2 Litigating more than one claim construction at trial: Federal Circuit review of record
§ 16:3 Special case: inherent infringement under single crystal theory
§ 16:4 —Impact of SmithKline v. Apotex on infringement
§ 16:5 Proving literal infringement
§ 16:6 Literal infringement as based on the generic drug application
§ 16:7 The ANDA specification controls the infringement inquiry
§ 16:8 Current ANDA infringement for future modifications to ANDA

CHAPTER 17. DOCTRINE OF EQUIVALENTS INFRINGEMENT

§ 17:1 Doctrine of equivalents (DOE) infringement
§ 17:2 Tests for DOE
§ 17:3 —General limitations on the doctrine of equivalents
§ 17:4 —Insubstantial differences test for equivalency infringement
§ 17:5 —Function way result test
§ 17:6 —Element-by-element analysis
§ 17:7 Expanding scope of equivalents to ensnare prior art—Ensnarement Test
§ 17:8 Subject matter disclosed but not claimed—“Dedication to the public” rule
§ 17:9 Doctrine of Prosecution History Estoppel (PHE)
§ 17:10 —Amendment-based estoppel
§ 17:11 — —Rebutting the presumption of estoppel
§ 17:12 — —Festo IX: Federal circuit summary of equivalency factors
§ 17:13 — —Festo Test Part 7: Rebutting prosecution history estoppel
TABLE OF CONTENTS

§ 17:14 — —Festo Test Part 7(i): Foreseeable changes
§ 17:15 — —Foreseeability of drafting claim to equivalent: Is it new matter?
§ 17:16 — —Festo Test Part 7(ii): Tangential relationship
§ 17:17 — —Festo test part 7(iii): Some other unexplained reason
§ 17:18 —Argument-based estoppel
§ 17:19 —Related applications may evoke estoppel
§ 17:20 —Scope
§ 17:21 —Prior art preclusions—Hypothetical claim analysis
§ 17:22 Doctrine of prosecution history estoppel (PHE)—Detailed structure test: An alternate to the insubstantial differences and function way result tests
§ 17:23 Case studies: SmithKline Beecham and Equivalency—Sustained release bupropion
§ 17:24 —Conclusion
§ 17:25 DOE as applied to the word “about"

CHAPTER 18. INDIRECT INFRINGEMENT THROUGH INDUCEMENT AND CONTRIBUTORY INFRINGEMENT

§ 18:1 Contributory and inducement infringement generally
§ 18:3 The RLD label when taken as a whole—non-infringing uses
§ 18:4 Pleading and proving specific intent
§ 18:5 Strategies to mitigate or thwart inducement to infringe claims
§ 18:6 —Opinions of counsel of invalidity to thwart specific intent to induce infringement
§ 18:8 Inducement to infringe a patent claiming an unapproved FDA use—pointing to other section of label to prove inducement
§ 18:9 Contributory patent infringement under 35 U.S.C.A. § 271(c)
§ 18:10  — Knowing component is especially made
§ 18:11  — Substantial, noninfringing uses
§ 18:12  — Materiality

CHAPTER 19. INEQUITABLE CONDUCT AND PATENT UNENFORCEABILITY

§ 19:1  Inequitable conduct—Fraud on the Patent Office
§ 19:2  Types of inequitable conduct test—Common situations
§ 19:3  Penalties for inequitable conduct
§ 19:4  — Unenforceability—Later patents through infectious unenforceability
§ 19:5  — Awarding attorney's fees and costs
§ 19:6  — Fraud-based damages (Walker Process fraud)
§ 19:7  — Private enforcement of fraud
§ 19:8  Curing inequitable conduct
§ 19:9  Asserting inequitable conduct—Not a game of “gotcha”
§ 19:10  — Pleading inequitable conduct under heightened pleading standards
§ 19:11  Materiality threshold—Current and past tests for materiality
§ 19:12  — Information does not have to be claimed
§ 19:13  — Failure to comply with section 112(1)
§ 19:14  — Information does not have to verbatim
§ 19:15  — False statements
§ 19:16  — Failure to disclose relationship of affiant to applicant
§ 19:17  — Data is presumed material
§ 19:18  — Failure to update information—petitions to make special
§ 19:19  — Failure to provide unfavorable test results
§ 19:20  — Accurate description of test conditions
§ 19:21  — Claim for priority
§ 19:22  — Issues examiner focuses on
§ 19:23  — Affirmative misrepresentations
§ 19:24  Intent to deceive
§ 19:25  — Stressing importance of submitted prior art
§ 19:26  — Gross negligence
§ 19:27  — “Totality” can include gross negligence
§ 19:28  — Mere denial is never enough to overcome inference of intent
§ 21:3 Hatch Waxman Act/safe harbor exemption—
Scope of exemption
§ 21:4 “Information” development and “information”
submission to FDA
§ 21:5 Reasonable scope of exemption
§ 21:6 —Medical devices and other ostensibly unrelated
activities
§ 21:7 —Effect of Congressional action on scope of
exemption
§ 21:8 —Chain of exemption
§ 21:9 — —Generic drug development
§ 21:10 — —Ancillary activities
§ 21:11 Recourse for patent holders
§ 21:12 Common law research exemption and de
minimis infringement
§ 21:13 Safe harbor exemption is not limited to just
generic drug development
§ 21:14 Safe harbor exemption and stock-piling
inventory

CHAPTER 22. BASICS OF BRAND DRUG
APPROVAL PROCESS AND ORANGE
BOOK LISTINGS
§ 22:1 Introduction
§ 22:2 Brand drug approval
§ 22:3 Investigational new drug application (IND)—
Beginning clinical trials
§ 22:4 —Contents
§ 22:5 New drug application (NDA)
§ 22:6 —Drug master files (DMF)
§ 22:7 Types of new drugs in NDA
§ 22:8 Internal FDA machinations
§ 22:9 Patent information and the Orange Book
§ 22:10 —Listable and nonlistable patents
§ 22:11 —Patent listing as clerical not substantive
§ 22:12 —Delisting patents
§ 22:13 —Forcible listing of unlisted patents
§ 22:14 When patents may be listed
§ 22:15 Who may list which patents
§ 22:16 Medical device patents and antibiotic patents—
Status
§ 22:17 Polymorph patent listing
TABLE OF CONTENTS

§ 22:18 Blinds and clinical testing
§ 22:19 —Clinical trial phases
§ 22:20 —Clinical trial phases—Public use patent invalidity
§ 22:21 “Paper NDAs”—New Drug Applications/section 505(b)(2) applications
§ 22:22 NDA approval and approval dates

CHAPTER 23. BRAND SIDE EXCLUSIVITIES

§ 23:1 Filing and approval exclusivities
§ 23:2 New Chemical Entity (NCE) exclusivity [five-year]
§ 23:3 NCE exclusivity and DEA scheduling
§ 23:4 NCE exclusivity for fixed combination products
§ 23:5 Extension of five year NCE exclusivity to 10 year NCE (and three year exclusivity) under qualified infectious disease products program
§ 23:6 Contrasting New Molecules for NCE Status versus New Molecules for Patent Term Extension (PTE) Purposes
§ 23:7 New Chemical Entity (NCE) exclusivity [five-year]—When to file ANDAs with Paragraph IV certifications
§ 23:8 —Extensions of the 30-month stay to Year 7.5 for NCE-based lawsuits
§ 23:9 —Delisting patents from Orange Book right before NCE-1 date to thwart generic filings
§ 23:10 New product/clinical information/supplemental exclusivity [three-year]
§ 23:11 —Requirements for the new clinical information exclusivity
§ 23:12 —Requirements—Working example for generic approval of less than all indications
§ 23:13 —Difference between NCE and three-year exclusivity
§ 23:14 Three-year exclusivity for enantiomers
§ 23:15 Orphan drug exclusivity [seven-year exclusivity]
§ 23:16 Pediatric exclusivity [six months]
§ 23:17 —Effect
§ 23:18 —Tracking
§ 23:19 —Effect on ANDA filings
§ 23:20 —Effect on the 30-month stay

xxxvii
§ 23:21 — —Working examples of pediatric exclusivity
§ 23:22 — —Working examples—Ranbaxy v. FDA and Pfizer; fluconazole
§ 23:23 — — —Alza v. Mylan/Mylan v. FDA; fentanyl patch
§ 23:24 —Effects on the 30-month stay—Working examples—Pfizer v. Apotex; amlodipine
§ 23:25 —Pediatric exclusivity and combination products
§ 23:26 Patent infringement implications
§ 23:27 Key points about pediatric exclusivity

CHAPTER 24. “PAPER NDA” AND SECTION 505(B)(2) APPLICATIONS
§ 24:1 Section 505(b)(2) application—General principles
§ 24:2 Contrasting 505(b)(2) applications with Abbreviated New Drug Applications (ANDA)
§ 24:3 Similarities between 505(b)(2) application and ANDA
§ 24:4 General types of applications
§ 24:5 Information needed to support the application
§ 24:6 Strategic uses
§ 24:7 —Use of a 505(b)(2) application to circumvent the 180-day exclusivity
§ 24:8 Challenges to the 505(b)(2)’s reference listed drug
§ 24:9 Conclusion

CHAPTER 25. ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVAL PROCESS
§ 25:1 Reference Listed Drug (RLD)
§ 25:2 Suitability petitions to refer to different RLDs
§ 25:3 Abbreviated New Drug Application (ANDA)
§ 25:4 ANDA submissions standards & impact of refusal to receive (RTR)
§ 25:5 Challenging the refusal to receive (RTR) decision: no private right of action to enforce the FDCA
§ 25:6 Abbreviated New Drug Application (ANDA)—Differences between the NDA and ANDA
§ 25:7 —Last minute RLD label changes to thwart generic competition
§ 25:8 —Bioequivalency of generic drug

xxxviii
TABLE OF CONTENTS

§ 25:9 Access to the RLD when RLD is protected by REMS
§ 25:10 Inner workings of the FDA
§ 25:11 Labeling review
§ 25:12 Chemistry and Manufacturing Controls (CMC)
§ 25:13 Biopharmaceutical review and bioavailability
§ 25:14 Classification system for biopharmaceutical properties
§ 25:15 —Patents claiming pharmacokinetics
§ 25:16 Microbiology review
§ 25:17 Clinical review
§ 25:18 CGMP review
§ 25:19 Deficiency letters
§ 25:20 —Major deficiency
§ 25:21 —Minor deficiency letter
§ 25:22 — —Telephone amendment
§ 25:23 Approval matrix
§ 25:24 Final approval versus tentative approval
§ 25:25 Tentative approval—Reasons for getting it
§ 25:26 Patent attorney involvement in answering deficiency letters
§ 25:27 Showing bioequivalence of generic versions
§ 25:28 Bioavailability defined
§ 25:29 Bioequivalence defined
§ 25:30 Measuring bioequivalence of traditional solid oral dosage forms—Immediate and extended release forms
§ 25:31 —Extended release (ER) forms
§ 25:32 Extended release types—Diffusion control system
§ 25:33 —Dissolution control system
§ 25:34 —Erosion control system
§ 25:35 —Osmotic pump system
§ 25:36 —Ion-exchange resin system
§ 25:37 Proving bioequivalency—Failed biostudies as evidence of non-obviousness
§ 25:38 —In vitro dissolution studies
§ 25:39 —Dissolution testing and standardized testing protocols
§ 25:40 —Particle size and dissolution testing
§ 25:41 In vitro bioequivalence (BE) testing—Reasons for BE testing and biowaivers
§ 25:42 Biostudies in human subjects—Pilot and pivotal biostudies
§ 26:7 —Patent certifications to “pop up” and “late listed” patents
§ 26:8 —ANDA certifications when the current RLD itself referred to a previous RLD
§ 26:9 —Impact on ANDA approval
§ 26:10 —Hypothetical patent certifications—Case study on Viagra
§ 26:11 Section viii statements: omitting patented methods of use
§ 26:12 Section (viii) statements: omitting patented methods of use—Use codes, patent infringement, and carve outs
§ 26:13 —Working example on Section viii statements—Sertraline
§ 26:14 —One and only indication
§ 26:15 —Carving out indications to unlisted patents
§ 26:16 —Request listing of currently unlisted method of use patent
§ 26:17 —Using suitability petitions to allow carve out
§ 26:18 Combining Paragraph I certification in lieu of Section viii statement
§ 26:19 Paragraph IV certification and notice letter requirements
§ 26:20 —Paragraph IV certification to just one claim of just one patent
§ 26:21 —Identifying the patents in the notice letter
§ 26:22 —Content and sufficiency of the notice letter
§ 26:23 —How much detail is necessary
§ 26:24 —Details on claims that are not normally listable
§ 26:25 —Form of letter and detailed statement
§ 26:26 —Appending letter to a complaint
§ 26:27 —Predicates to antitrust injury
§ 26:28 —How to send the notice letter
§ 26:29 —Where to send the notice letter
§ 26:30 —When to send the notice letter
§ 26:31 —Sending Paragraph IV Notice Letters before ANDA is officially submitted/received
§ 26:32 —Updating the FDA on notice letters
§ 26:33 Reissue patents: new patents or rollovers of old patents that require new patent certifications
§ 26:34 —Summary
§ 26:35 Offer for Confidential Access (OCA)
§ 26:36 —Where invalidity is alleged
CHAPTER 27. THE 30-MONTH INJUNCTION/STAY

I. GENERALLY

§ 27:1 Introduction
§ 27:2 Creating the 30-month stay and counting days
§ 27:3 The “frozen” Orange Book and patents that qualify for 30-month stays
§ 27:4 Who notifies the FDA of the lawsuit

II. TERMINATION OF THE 30-MONTH STAY

§ 27:5 How the 30-month stay is normally terminated
§ 27:6 Court decision to terminate a stay
§ 27:7 Generic company wins at trial level
§ 27:8 Generic company wins on appeal
§ 27:9 Patentee delays

III. LENGTHENING, SHORTENING, OR REINSTATING THE STAY

§ 27:10 Extending stay because court made no decision
§ 27:11 Reinstating if wrongfully terminated
§ 27:12 Lengthening or shortening due to lack of cooperation
§ 27:13 Cases extending the 30-month stay
§ 27:14 Generic Company Request to Elongate 30-month
stay to avoid forfeiture because the generic company “filed too early”

§ 27:15 Cases shortening the 30-month stay
§ 27:16 Cases where the stay was not altered despite request to alter

IV. EFFECT OF DELAYS

§ 27:17 Missing the 45-day window—Can suit still be brought?

V. EARNING NEW 30-MONTH STAYS

§ 27:18 Generally
§ 27:19 Repetitive 30-month stays under the old rules
§ 27:20 Earning 30-month stays under the December 2003 rules
§ 27:21 Effect of “pop-up” (newly issued) patents
§ 27:22 Reformulation may cause new 30-month stay
§ 27:23 Working examples of the 30-month stay

VI. STAGGERED EXPIRATIONS

§ 27:24 Multiple applicants 30-month stay; staggered stay expiries
§ 27:25 Stay of court decision pending appeal to maintain 30-month stay intact: case study in oxaliplatin
§ 27:26 Extending the 30-month stay to year 7.5 after New Chemical Entity (NCE) exclusivity
§ 27:27 Impact of pending Inter Partes Reviews (IPR) on 30-month stays

CHAPTER 28. THE PARAGRAPH IV BASED 180-DAY EXCLUSIVITY

§ 28:1 Introduction
§ 28:2 Creating the 180-day exclusivity
§ 28:3 Against whom the 180-day exclusivity applies
§ 28:4 FDA’s patent-by-patent approach to patent certifications in pre-MMA Dec. 2003
§ 28:5 Product-by-product approach to exclusivity
§ 28:6 180-day exclusivity naturally expires with the underlying patent
§ 28:7 Triggering the 180-day exclusivity clock
CHAPTER 29. FORFEITURE OF THE 180-DAY EXCLUSIVITY

§ 29:1 Introduction
§ 29:2 Forfeiture provisions
§ 29:3 —Failure to market
§ 29:4 Failure to market under little (aa); 30 months to approval, 75 days to market
§ 29:5 Failure to market under little (bb)
§ 29:6 —Court decision litigant needs to have tentative approval to trigger
§ 29:7 —Does the court litigant triggering little (bb) have to be the same ANDA applicant that has tentative approval?
§ 29:8 —What kind of court decision is needed to trigger under little (bb)?
§ 29:9 Estoppel effect of judgment and parties vacating judgment to avoid estoppel
§ 29:10 New America Invents Act Procedures should not create, by itself, a little (bb) event
§ 29:11 Rationale for little (bb)'s patent position versus little (aa)'s regulatory position
§ 29:12 Effect of patentee delisting Orange Book patents
to create date-certain forfeiture event under
little (bb)/Big (CC)—Case study: Dorzolomide +
Timolol (Cosopt®)

§ 29:13 Effect of patentee delisting of Orange Book
patents to create date-certain forfeiture event
under little (bb)/Big (CC)—Case study:
acarbose (Precose®)

§ 29:14 Effect of patentee delisting of Orange Book
patents to create date certain forfeiture event
under little (bb)/Big (CC)—Case study:
Losartan (Cozaar®)

§ 29:15 Failure to market: no delisting and no
litigation—Case study: Granisetron (Kytril)

§ 29:16 Coercive agreements; settling lawsuits but
maintaining paragraph IV to avoid forfeit

§ 29:17 —Case study: Ramipril (Altace)

§ 29:18 Withdrawal of application

§ 29:19 Amendment of certification

§ 29:20 Failure to obtain tentative approval in 30
months

§ 29:21 Failure to obtain tentative approval in 30
months & Impact of GMP Compliance

§ 29:22 Concurrent qualification and forfeiture due to
failure to obtain tentative approval in 30-
months: Adding a new para. IV certification
can cause immediate forfeiture

§ 29:23 The statutory (non-statutory) basis for
calculating the 30-months to obtain tentative
approval may belie or support the FDA’s
interpretation

§ 29:24 New FDASIA law of 09 July 2012 statutorily
overrules FDA interpretation that led to
simultaneous grant of exclusivity and forfeiture

§ 29:25 New FDASIA law extends 30-month period to
obtain tentative approval to avoid forfeiture

§ 29:26 Failure to obtain tentative approval in 30
months—Is “within 30 months” really in 30
months or is it day one of the 31st month?
Computation of time

§ 29:27 Computation of time for obtaining approval
“within 30 months” and policy considerations

§ 29:28 Failure to obtain tentative approval in 30
months—Case study: Irinotecan (Campostar)
and famotidine Chewable (Pepcid Complete)
§ 29:29 Failure to obtain tentative approval—Tentative approval, changed conditions, and citizen petitions
§ 29:30 Failure to obtain tentative approval in 30-months: instances where no forfeiture occurred because of changed circumstances
§ 29:31 ANDA review backlog at FDA increases mean ANDA approval time possibly causing forfeitures
§ 29:32 No-rolling exclusivity
§ 29:33 Expiration of patents
§ 29:34 —Multiple patents confer exclusivity
§ 29:35 Forfeiting applicant does not go to the back of the bus nor do back seaters come forward—Case study of nateglinide (Starlix®)
§ 29:36 Forfeitures in general policy terms; vested property right
§ 29:37 Forfeitures for filing the ANDA “too early”
§ 29:38 Forfeiture of the 180-day exclusivity: Intentional forfeiture

CHAPTER 30. 180 DAY MARKET EXCLUSIVITY UNDER COMPETITIVE GENERIC THERAPY (CGT) INITIATIVE
§ 30:1 About the Competitive Generic Therapies (CGT) initiative
§ 30:2 Qualifying for the CGT
§ 30:3 Inadequate generic competition
§ 30:4 Securing CGT 180-day exclusivity and losing it
§ 30:5 General commentary on the new CGT
§ 30:6 Should FDA wait 75-Days to see if CGT ANDA sponsor launches before approving other ANDA’s?
§ 30:7 Relevant statutory provisions of the CGT 180-Day exclusivity and forfeiture

CHAPTER 31. PREISSUE SUBMISSIONS AND POST-ISSUANCE IPR WITH IMPACTS ON COURT LITIGATION
§ 31:1 Cleaning up patent quality before or after a patent issues
§ 31:2 Preissue submissions to interject into a pending application
§ 31:3 Post-issuance procedures to invalidate a patent
§ 31:4 Post Grant Review (PGR) and Inter Partes Review (IPR)
§ 31:5 Potential impacts of IPR’s on parallel patent litigation
§ 31:6 —Timing of IPR/Appeals & Standing to Appeal
§ 31:7 —Denial of IPR petition and subjective effect of perceptual estoppel
§ 31:8 —Using denied IPR petition as roadmap to correct or summary judgment of no invalidity
§ 31:9 —Instituted IPR to deny TRO/Preliminary Injunction (PI)
§ 31:10 —Petitioner losing at PTAB
§ 31:11 —Patentee losing at PTAB
§ 31:12 —To cause forfeiture of 180-Day exclusivity by getting a “court decision” for failure to market

CHAPTER 32. PATENT INFRINGEMENT DAMAGES AND REMEDIES
§ 32:1 Introduction
§ 32:2 Potential remedies for patent infringement
§ 32:3 Impact of the loss on the ANDA approval status and redating the ANDA approval date
§ 32:4 Redating the ANDA approval date is not permissible if the infringing activities were under sections 271(a), (b), and (c)
§ 32:5 Impact of the loss on the ANDA approval status and redating the ANDA approval date—ANDAs for old antibiotics should not have redated approval dates
§ 32:6 Injunctive relief to stop future infringement or prevent at-risk launch
§ 32:7 —Other factors to consider in whether to grant a launch-prevention injunction
§ 32:8 Awarding an injunction against future infringement when generic company loses
§ 32:9 Product recall of generic products in the marketplace
§ 32:10 Money damages for patent infringement
§ 32:11 Patent damages for post-publication of patent to patent issuance under provisional rights under Section 154(d)
§ 32:12 Money damages for patent infringement—Money damages, reasonable royalty or lost profits
§ 33:2 When DJs are used in pharmaceutical patent cases
§ 33:3 Traditional declaratory judgment standards
§ 33:4 Post-MedImmune declaratory judgment standards
§ 33:5 Post-MedImmune declaratory judgment standards—Famciclovir case and factors allowing a declaratory judgment action
§ 33:6 Declaratory judgments to trigger exclusivity
§ 33:7 —Is tentative approval needed before filing a DJ?
§ 33:8 —Orange Book listing alone could confer DJ jurisdiction
§ 33:9 ——Patents listed but statutorily disclaimed may or may not confer jurisdiction
§ 33:10 Covenants not to sue; removing fear of suit
§ 33:11 —Covenants divesting court’s jurisdiction
§ 33:12 Declaratory judgment updates
§ 33:13 —DJ’s and offers for confidential access
§ 33:14 —Is enforcement of an offer for confidential access an improper private right of action

CHAPTER 34. CITIZEN PETITIONS
§ 34:1 What is a citizen petition
§ 34:2 Form of the citizen petition
§ 34:3 Time period for FDA to respond
§ 34:4 What is an FDA response?
§ 34:5 Potential antitrust penalties for sham citizen petitions
§ 34:6 Implications of citizen petition denial and ANDA approvals
§ 34:7 Citizen petitions by generic companies

CHAPTER 35. ISSUES RELATING TO THE SIZE/SHAPE/COLOR OF GENERIC PRODUCTS
§ 35:1 Size, shape, and color of generic products
§ 35:2 Functionality of generic drug product as defense to trademark infringement
§ 35:3 Cases involving generic drug product size, shape, or color
CHAPTER 36. PHARMACEUTICAL COMPOUNDING AND INTELLECTUAL PROPERTY ISSUES
§ 36:1 Introduction to drug product compounding
§ 36:2 FDA authority over compounded drug products
§ 36:3 Patent infringement issues in compounding
§ 36:4 False advertising issues in compounding
§ 36:5 Animal drugs are subject to compounding problems too

CHAPTER 37. OVER THE COUNTER (OTC) DRUGS
§ 37:1 Overview of prescription versus over the counter (OTC) drugs
§ 37:2 OTC drugs and the orange book
§ 37:3 ANDA filing against OTC NDA drug product
§ 37:4 Prescription to OTC switches
§ 37:5 ANDA commercial issues in the Rx to OTC switch

APPENDICES
Appendix A. 355
Appendix A-1. Annotations to 21 U.S.C. 355f
Appendix B. Annotations to 35 U.S.C.

Glossary
Table of Cases
Index